- Eli Lilly CEO Dave Ricks said one-third of new GLP-1 pill patients are starting on the company's oral drug Foundayo, with Lilly's share of the oral market growing week over week.
- Lilly broke ground on a $6.5 billion manufacturing facility at Generation Park in Houston, Texas, expected to be operational by 2030 and to produce Foundayo's active ingredient alongside other small-molecule medicines.
- 700,000 U.S. seniors have started on GLP-1s following the start of Medicare coverage on July 1, and 70% of those patients are on Lilly's drugs.
- Lilly held about a 61% share of the overall obesity and diabetes market in Q2, while Novo shares fell after its long-term strategy failed to assuage investor concerns about competing with Lilly.
Quotes
“We're confident long term”